Christine Ring Sells 9,050 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 9,050 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $24.94, for a total transaction of $225,707.00. Following the completion of the transaction, the insider now owns 24,592 shares of the company’s stock, valued at $613,324.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Christine Ring also recently made the following trade(s):

• On Monday, August 26th, Christine Ring sold 9,870 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.01, for a total value of $246,848.70.
• On Thursday, August 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $21.43, for a total value of $123,436.80.
• On Monday, July 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.81, for a total transaction of $119,865.60.
• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total transaction of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.00, for a total transaction of $6,800.00.

Nurix Therapeutics Stock Down 1.3 %

Nurix Therapeutics stock traded down $0.34 during mid-day trading on Tuesday, hitting $24.86. 677,887 shares of the company’s stock traded hands, compared to its average volume of 925,820. The company has a market cap of $1.60 billion, a PE ratio of -8.63 and a beta of 2.22. The firm has a 50 day moving average price of $21.87 and a 200 day moving average price of $17.07. Nurix Therapeutics, Inc. has a one year low of $4.22 and a one year high of $26.12.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. Massachusetts Financial Services Co. MA increased its position in shares of Nurix Therapeutics by 248.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 142,146 shares of the company’s stock valued at $1,467,000 after purchasing an additional 101,320 shares during the period. Affinity Asset Advisors LLC raised its position in Nurix Therapeutics by 176.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after acquiring an additional 440,112 shares in the last quarter. Trexquant Investment LP lifted its holdings in Nurix Therapeutics by 80.9% in the 4th quarter. Trexquant Investment LP now owns 159,318 shares of the company’s stock valued at $1,644,000 after acquiring an additional 71,252 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Nurix Therapeutics by 576.7% during the 1st quarter. Acadian Asset Management LLC now owns 160,293 shares of the company’s stock valued at $2,355,000 after purchasing an additional 136,606 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Nurix Therapeutics by 365.0% in the 2nd quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock worth $2,154,000 after purchasing an additional 81,005 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NRIX. Stifel Nicolaus reissued a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, May 15th. JPMorgan Chase & Co. raised their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Stephens began coverage on shares of Nurix Therapeutics in a research note on Tuesday, May 14th. They set an “overweight” rating and a $20.00 target price for the company. Barclays lifted their price target on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Finally, Oppenheimer increased their price objective on shares of Nurix Therapeutics from $25.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.69.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.